TY - JOUR
T1 - A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
AU - Sonbol, Mohamad Bassam
AU - Hilal, Talal
AU - Dueck, Amylou C.
AU - Rosenthal, Allison C.
AU - Conley, Christopher R.
AU - Kosiorek, Heidi E.
AU - Ginos, Brenda F.
AU - Gano, Katherine M.
AU - Nichols, Craig S.
AU - Leis, Jose F.
AU - Johnston, Patrick B.
AU - Habermann, Thomas M.
AU - Northfelt, Donald W.
AU - Bergsagel, Peter Leif
AU - Inwards, David J.
AU - Witzig, Thomas E.
AU - Ansell, Stephen M.
AU - Reeder, Craig B.
N1 - Funding Information:
The study was supported by Takeda Pharmaceuticals North America.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/9/2
Y1 - 2018/9/2
N2 - In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m 2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51–80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.
AB - In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m 2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51–80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile.
KW - CyBorD
KW - Non-Hodgkin lymphoma
KW - follicular lymphoma
KW - mantle cell lymphoma
KW - phase II trials
UR - http://www.scopus.com/inward/record.url?scp=85041124984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041124984&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1416368
DO - 10.1080/10428194.2017.1416368
M3 - Article
C2 - 29320913
AN - SCOPUS:85041124984
SN - 1042-8194
VL - 59
SP - 2128
EP - 2134
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -